Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy

Authors:
  • DNDrcr Retina Network
    Drcr Retina Network

Abstract
Vitreous hemorrhage is common in patients with proliferative diabetic retinopathy (PDR) and can cause severe vision loss.1 Despite treatment with panretinal photocoagulation (PRP) or intravitreous ranibizumab for PDR, almost half of the eyes in the DRCR Retina Network Protocol S developed vitreous hemorrhage during 5 years of follow-up.2 Although vitreous hemorrhage can clear spontaneously, intervention may hasten visual recovery. Once the clinician and patient decide that intervention for the vitreous hemorrhage is needed, treatment options include injections of anti–vascular endothelial growth factor (anti-VEGF) agents to cause regression of neovascularization while the vitreous hemorrhage is reabsorbed or surgical removal of the vitreous hemorrhage and neovascular membranes with vitrectomy plus PRP.

This publication has 7 references indexed in Scilit: